R964C mutation of DNA polymerase γ imparts increased stavudine toxicity by decreasing nucleoside analog discrimination and impairing polymerase activity

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 6, 2009, Pages 2610-2612

  Bailey, Christopher M ^a   Kasiviswanathan, Rajesh ^b   Copeland, William C ^b   Anderson, Karen S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DIRECTED DNA POLYMERASE GAMMA; DRUG METABOLITE; HOLOENZYME; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ARTICLE; DRUG DISCRIMINATION; ENZYME ACTIVITY; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; MITOCHONDRIAL TOXICITY; PRIORITY JOURNAL; STEADY STATE; WILD TYPE;

ANTI-HIV AGENTS; DNA-DIRECTED DNA POLYMERASE; HUMANS; MITOCHONDRIA; MUTATION; STAVUDINE; THYMINE NUCLEOTIDES;

EID: 67049145568     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01659-08     Document Type: Article

References (22)

1. Astatke, M., N. D. Grindley, and C. M. Joyce. 1998. How E. coli DNA polymerase I (Klenow fragment) distinguishes between deoxy- and dideoxynucleotides. J. Mol. Biol. 278:147-165.
2. Brinkman, K., and T. N. Kakuda. 2000. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr. Opin. Infect. Dis. 13:5-11.
3. Chan, S. S., and W. C. Copeland. DNA polymerase gamma and mitochondrial disease: understanding the consequence of POLG mutations. Biochim. Biophys. Acta, in press.
4. Chiappini, F., E. Teicher, R. Saffroy, B. Debuire, D. Vittecoq, and A. Lemoine. 2009. Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study. Curr. HIV Res. 7:244-253.
5. Feng, J. Y., A. A. Johnson, K. A. Johnson, and K. S. Anderson. 2001. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J. Biol. Chem. 276:23832-23837.
6. Graves, S. W., A. A. Johnson, and K. A. Johnson. 1998. Expression, purifi- cation, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase. Biochemistry 37:6050-6058. (Pubitemid 28196761)
7. Graziewicz, M. A., M. J. Longley, R. J. Bienstock, M. Zeviani, and W. C. Copeland. 2004. Structure-function defects of human mitochondrial DNA polymerase in autosomal dominant progressive external ophthalmoplegia. Nat. Struct. Mol. Biol. 11:770-776.
8. Hammer, S. M., J. J. Eron, Jr., P. Reiss, R. T. Schooley, M. A. Thompson, S. Walmsley, P. Cahn, M. A. Fischl, J. M. Gatell, M. S. Hirsch, D. M. Jacobsen, J. S. Montaner, D. D. Richman, P. G. Yeni, and P. A. Volberding. 2008. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300:555-570.
9. Johnson, A. A., A. S. Ray, J. Hanes, Z. Suo, J. M. Colacino, K. S. Anderson, and K. A. Johnson. 2001. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 276:40847-40857.
10. Johnson, A. A., Y. Tsai, S. W. Graves, and K. A. Johnson. 2000. Human mitochondrial DNA polymerase holoenzyme: reconstitution and characterization. Biochemistry 39:1702-1708. (Pubitemid 30108960)
11. Johnson, K. A. 1992. The enzymes, 4th ed., vol.20. Academic Press, New York, NY.
12. Johnson, K. A. 1995. Rapid quench kinetic analysis of polymerases, adenosinetriphosphatases, and enzyme intermediates. Methods Enzymol. 249:38-61.
13. Lewis, W., B. J. Day, and W. C. Copeland. 2003. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2:812-822.
14. Lim, S. E., and W. C. Copeland. 2001. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J. Biol. Chem. 276:23616-23623.
15. Lim, S. E., M. J. Longley, and W. C. Copeland. 1999. The mitochondrial p55 accessory subunit of human DNA polymerase gamma enhances DNA binding, promotes processive DNA synthesis, and confers N-ethylmaleimide resistance. J. Biol. Chem. 274:38197-38203. (Pubitemid 30026894)
16. Lim, S. E., M. V. Ponamarev, M. J. Longley, and W. C. Copeland. 2003. Structural determinants in human DNA polymerase gamma account for mitochondrial toxicity from nucleoside analogs. J. Mol. Biol. 329:45-57.
17. Longley, M. J., P. A. Ropp, S. E. Lim, and W. C. Copeland. 1998. Characterization of the native and recombinant catalytic subunit of human DNA polymerase gamma: identification of residues critical for exonuclease activity and dideoxynucleotide sensitivity. Biochemistry 37:10529-10539. (Pubitemid 28357578)
18. Ray, A. S., J. Y. Feng, E. Murakami, C. K. Chu, R. F. Schinazi, and K. S. Anderson. 2007. Interaction of 2′-deoxyguanosine triphosphate analogue inhibitors of HIV reverse transcriptase with human mitochondrial DNA polymerase gamma. Antivir. Chem. Chemother. 18:25-33.
19. Tabor, S., and C. C. Richardson. 1995. A single residue in DNA polymerases of the Escherichia coli DNA polymerase I family is critical for distinguishing between deoxy- and dideoxyribonucleotides. Proc. Natl. Acad. Sci. USA 92:6339-6343.
20. Wong, L. J., R. K. Naviaux, N. Brunetti-Pierri, Q. Zhang, E. S. Schmitt, C. Truong, M. Milone, B. H. Cohen, B. Wical, J. Ganesh, A. A. Basinger, B. K. Burton, K. Swoboda, D. L. Gilbert, A. Vanderver, R. P. Saneto, B. Maranda, G. Arnold, J. E. Abdenur, P. J. Waters, and W. C. Copeland. 2008. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum. Mutat. 29:E150-E172.
21. Yakubovskaya, E., Z. Chen, J. A. Carrodeguas, C. Kisker, and D. F. Bogenhagen. 2006. Functional human mitochondrial DNA polymerase gamma forms a heterotrimer. J. Biol. Chem. 281:374-382.
22. Yamanaka, H., H. Gatanaga, P. Kosalaraksa, S. Matsuoka-Aizawa, T. Takahashi, S. Kimura, and S. Oka. 2007. Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment. J. Infect. Dis. 195:1419-1425.